Systematic review of epigenetic targets in acute myeloid leukemia

xlomafota13 shared this article with you from Inoreader Systematic review of epigenetic targets in acute myeloid leukemia Via American Journal of Blood Research Am J Blood Res. 2021 Oct 15;11(5):458-471. eCollection 2021. ABSTRACT Acute myeloid leukemia (AML), although genetically and morphologically distinct from other B and T cell ALL subtypes, has one of the most rapidly progressing course and worse outcomes. The current diagnostic classification of AML offers best curative intent, the outcomes are not usually those that are expected at the start of therapy. This is partly attributed to the complex mechanism of leukemogenesis and resistance to chemotherapy. The underlying genetic mechanism of resistance is as complex as is the disease etiopathogenesis. Recent advances in therapy of drug resistant AML highlight the role of epigenetic targets. New FDA approved targeted therapy has also provided some evidence at improving outcomes in clinical trials. This review provides a detailed review of FDA approved targets and ongoing clinical trials for targeting CRISPER, CAR-T and other intestinal moda lities for approach to epigenetictargets. However, this group of epigenetic targeted therapy needs more validation to prove its clinical efficacy. A systematic review of all published research on these targets, investigational agents and FDA approved targeted therapy summarizes this evidence. It also takes us through a brief review of mechanism of action and targets for therapy. PMID:34824880 | PMC:PMC8610793 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.